Hyperphosphatasia with mental retardation syndrome 3: Cerebrospinal fluid abnormalities and correction with pyridoxine and Folinic acid
JIMD Reports · 2023-01 · 64 (1) · 42-52
DOI: 10.1002/jmd2.12347 ↗Kurz gefasst
Fallbericht in der Zeitschrift JIMD Reports, online erschienen am 22.11.2022. Verfasst von Martina Messina und 4 weiteren Autor:innen. Beteiligte Einrichtung: Metabolic Medicine Department Great Ormond Street Hospital for Children London UK. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council.
Abstract (Originalsprache)
Glycosylphosphatidylinositol anchored proteins (GPI‐APs) represent a class of molecules attached to the external leaflet of the plasma membrane by the GPI anchor where they play important roles in numerous cellular processes including neurogenesis, cell adhesion, immune response and signalling. Within the group of GPI anchor defects, six present with the clinical phenotype of Hyperphosphatasia with Mental Retardation Syndrome (HPMRS, Mabry Syndrome) characterized by moderate to severe intellectual disability, dysmorphic features, hypotonia, seizures and persistent hyperphosphatasia. We report the case of a 5‐year‐old female with global developmental delay associated with precocious puberty and persistently raised plasma alkaline phosphatase. Targeted next generation sequencing analysis of the HPMRS genes identified novel compound heterozygous variants in the PGAP2 gene (c.103del p.(Leu35Serfs*90)and c.134A > Gp.(His45Arg)) consistent with the diagnosis of HPMRS type 3. Cerebrospinal fluid (CSF) neurotransmitter analysis showed low levels of pyridoxal phosphate and 5‐methyltetrahydrofolate and raised homovanillic acid. Supplementation with pyridoxine and folinic acid led to normalization of biochemical abnormalities. The patient continues to make developmental progress with significant improvement in speech and fine motor skills. Our reported case expands the clinical spectrum of HPMRS3 in which multisystem involvement is being increasingly recognized. Furthermore, it shows that miss‐targeting GPI‐APs and the effect on normal cellular function could provide a physiopathologic explanation for the CSF biochemical abnormalities with management implications for a group of disorders that currently has no treatment that can lead possibly to improved clinical outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Metabolic Medicine Department Great Ormond Street Hospital for Children London UK.
- North Thames Genomic Laboratory Hub Great Ormond Street Hospital for Children London UK.
- University College London Great Ormond Street Institute for Children London UK.
ORCID-Profile: Spyros Batzios
Förderung
- Medical Research Council
Zitieren
APA
Messina, M., Manea, E., Cullup, T., Tuschl, K., & Batzios, S. (2023). Hyperphosphatasia with mental retardation syndrome 3: Cerebrospinal fluid abnormalities and correction with pyridoxine and Folinic acid. JIMD Reports, 64(1), 42-52. https://doi.org/10.1002/jmd2.12347
Vancouver
Messina M, Manea E, Cullup T, Tuschl K, Batzios S. Hyperphosphatasia with mental retardation syndrome 3: Cerebrospinal fluid abnormalities and correction with pyridoxine and Folinic acid. JIMD Reports. 2023;64(1):42-52. doi:10.1002/jmd2.12347
BibTeX
@article{Messina2023,
author = {Messina, Martina and Manea, Emanuela and Cullup, Thomas and Tuschl, Karin and Batzios, Spyros},
title = {Hyperphosphatasia with mental retardation syndrome 3: Cerebrospinal fluid abnormalities and correction with pyridoxine and Folinic acid},
journal = {JIMD Reports},
year = {2023},
volume = {64},
number = {1},
pages = {42--52},
doi = {10.1002/jmd2.12347}
}
EUVIMED